Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.

Wang Y, Li YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ.

Elife. 2018 Mar 12;7. pii: e36414. doi: 10.7554/eLife.36414. No abstract available.

2.

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Oct 31;6. pii: e33173. doi: 10.7554/eLife.33173. No abstract available.

3.

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR.

Cell. 2017 Jul 27;170(3):577-592.e10. doi: 10.1016/j.cell.2017.07.005.

4.

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Feb 1;6. pii: e18970. doi: 10.7554/eLife.18970. Erratum in: Elife. 2017 Oct 31;6:.

5.

CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.

Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G, DeWeck A, Abramowski D, Wan J, Shirley MD, Neshat SY, Rakiec D, de Beaumont R, Weber O, Kauffmann A, McDonald ER 3rd, Keen N, Hofmann F, Sellers WR, Schmelzle T, Stegmeier F, Schlabach MR.

Cancer Discov. 2016 Aug;6(8):900-13. doi: 10.1158/2159-8290.CD-16-0178. Epub 2016 Jun 3.

6.

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.

Mavrakis KJ, McDonald ER 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, Yan-Neale Y, Yang G, Lin F, Yin H, Gao H, Kipp DR, Zhao S, McNamara JT, Sprague ER, Zheng B, Lin Y, Cho YS, Gu J, Crawford K, Ciccone D, Vitari AC, Lai A, Capka V, Hurov K, Porter JA, Tallarico J, Mickanin C, Lees E, Pagliarini R, Keen N, Schmelzle T, Hofmann F, Stegmeier F, Sellers WR.

Science. 2016 Mar 11;351(6278):1208-13. doi: 10.1126/science.aad5944. Epub 2016 Feb 11.

7.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA.

Nat Med. 2016 Mar;22(3):262-9. doi: 10.1038/nm.4040. Epub 2016 Feb 1.

8.

TERT promoter mutations and monoallelic activation of TERT in cancer.

Huang FW, Bielski CM, Rinne ML, Hahn WC, Sellers WR, Stegmeier F, Garraway LA, Kryukov GV.

Oncogenesis. 2015 Dec 14;4:e176. doi: 10.1038/oncsis.2015.39.

9.

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.

Lantermann AB, Chen D, McCutcheon K, Hoffman G, Frias E, Ruddy D, Rakiec D, Korn J, McAllister G, Stegmeier F, Meyer MJ, Sharma SV.

Cancer Res. 2015 Nov 15;75(22):4937-48. doi: 10.1158/0008-5472.CAN-15-1113. Epub 2015 Oct 21.

10.

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F.

Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13.

PMID:
25849130
11.

A chemical genetics approach for the functional assessment of novel cancer genes.

Zhou Q, Derti A, Ruddy D, Rakiec D, Kao I, Lira M, Gibaja V, Chan H, Yang Y, Min J, Schlabach MR, Stegmeier F.

Cancer Res. 2015 May 15;75(10):1949-58. doi: 10.1158/0008-5472.CAN-14-2930. Epub 2015 Mar 18.

12.

MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.

Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ.

Elife. 2014 May 20;3:e01763. doi: 10.7554/eLife.01763. Erratum in: Elife. 2018 Mar 12;7:.

13.

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K, Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA, Keen N, McLaughlin ME, Mickanin C, Roberts CW, Stegmeier F, Jagani Z.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3128-33. doi: 10.1073/pnas.1316793111. Epub 2014 Feb 11.

14.

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F.

Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.

PMID:
24362935
15.

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.

Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E 3rd, Wei L, Ma J, Easton J, Yu Z, deBeaumount R, Gibaja V, Venkatesan K, Schlegel R, Sellers WR, Keen N, Liu J, Caponigro G, Barretina J, Cooke VG, Mullighan C, Carr SA, Downing JR, Garraway LA, Stegmeier F.

Nat Genet. 2013 Nov;45(11):1386-91. doi: 10.1038/ng.2777. Epub 2013 Sep 29.

16.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P.

Cancer Discov. 2013 Sep;3(9):1030-43. doi: 10.1158/2159-8290.CD-13-0142. Epub 2013 Jul 10.

17.

Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.

Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, Zhou W.

Oncotarget. 2013 Jun;4(6):816-29.

18.

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, Woolfenden S, Yu KK, Markovits J, Killary K, Sonkin D, Yao YM, Warmuth M, Sellers WR, Schlegel R, Stegmeier F, Mosher RE, McLaughlin ME.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17135-40. doi: 10.1073/pnas.1104182108. Epub 2011 Sep 23.

19.

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, Lenz P, Waters NJ, Schuler W, Dörken B, Yao YM, Warmuth M, Lenz G, Stegmeier F.

Cancer Res. 2011 Apr 1;71(7):2643-53. doi: 10.1158/0008-5472.CAN-10-2525. Epub 2011 Feb 15.

20.

The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome.

Song EJ, Werner SL, Neubauer J, Stegmeier F, Aspden J, Rio D, Harper JW, Elledge SJ, Kirschner MW, Rape M.

Genes Dev. 2010 Jul 1;24(13):1434-47. doi: 10.1101/gad.1925010.

21.

Targeted cancer therapies in the twenty-first century: lessons from imatinib.

Stegmeier F, Warmuth M, Sellers WR, Dorsch M.

Clin Pharmacol Ther. 2010 May;87(5):543-52. doi: 10.1038/clpt.2009.297. Epub 2010 Mar 17. Review.

PMID:
20237469
22.

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.

Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F.

Nature. 2009 Oct 1;461(7264):614-20. doi: 10.1038/nature08356. Epub 2009 Sep 16.

PMID:
19759537
23.

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F.

Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.

24.

PTEN-deficient cancers depend on PIK3CB.

Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28.

25.

The tumor suppressor CYLD regulates entry into mitosis.

Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8869-74. Epub 2007 May 10.

26.

Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities.

Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, McDonald ER 3rd, Li MZ, Hannon GJ, Sorger PK, Kirschner MW, Harper JW, Elledge SJ.

Nature. 2007 Apr 19;446(7138):876-81.

PMID:
17443180
27.

A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling.

Draviam VM, Stegmeier F, Nalepa G, Sowa ME, Chen J, Liang A, Hannon GJ, Sorger PK, Harper JW, Elledge SJ.

Nat Cell Biol. 2007 May;9(5):556-64. Epub 2007 Apr 8.

PMID:
17417629
28.

Dissecting cancer pathways and vulnerabilities with RNAi.

Westbrook TF, Stegmeier F, Elledge SJ.

Cold Spring Harb Symp Quant Biol. 2005;70:435-44. Review.

PMID:
16869781
29.
30.

A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.

Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ.

Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13212-7. Epub 2005 Sep 1.

31.

Closing mitosis: the functions of the Cdc14 phosphatase and its regulation.

Stegmeier F, Amon A.

Annu Rev Genet. 2004;38:203-32. Review.

PMID:
15568976
32.
33.

The replication fork block protein Fob1 functions as a negative regulator of the FEAR network.

Stegmeier F, Huang J, Rahal R, Zmolik J, Moazed D, Amon A.

Curr Biol. 2004 Mar 23;14(6):467-80.

34.

The role of the polo kinase Cdc5 in controlling Cdc14 localization.

Visintin R, Stegmeier F, Amon A.

Mol Biol Cell. 2003 Nov;14(11):4486-98. Epub 2003 Aug 7.

Supplemental Content

Loading ...
Support Center